Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck
- 441 Downloads
Boron neutron capture therapy (BNCT) is among the radiation treatments known to have a selective lethal effect on tumor cells. This study summarizes the tumor responses and the acute and late adverse effects of BNCT in the treatment of patients with both recurrent and newly diagnosed T4 salivary gland carcinoma.
Two patients with recurrent cancer and 3 with newly diagnosed T4 advanced malignancy were registered between October 2003 and September 2007, with the approval of the medical ethics committees of Kawasaki Medical School and Kyoto University. BNCT was performed, in a single fraction using an epithermal beam, at Japan Research Reactor 4.
All patients achieved a complete response within 6 months of treatment. The median duration of the complete response was 24.0 months; the median overall survival time was 32.0 months. Three of the 5 patients are still alive; the other 2 died of distant metastatic disease. Open biopsy of the parotid gland after BNCT was performed in 1 patient and revealed no residual viable cancer cells and no serious damage to the normal glandular system. Although mild alopecia, xerostomia, and fatigue occurred in all patients, there were no severe adverse effects of grade 3 or greater.
Our preliminary results demonstrate that BNCT is a potential curative therapy for patients with salivary gland carcinoma. The treatment does not cause any serious adverse effects, and may be used regardless of whether the primary tumor has been previously treated.
KeywordsBNCT Paraboronophenylalanine 18F-BPA PET Salivary gland carcinoma Radio-resistant cancers
This work was supported by JSPS Grant-in-Aid for Scientific Research (C) Number 24592611.
Conflict of interest
The authors declare that they have no conflict of interest. Teruhito Aihara have no personal or financial interests to declare and receive no financial support from an industry source related to the current manuscript.
- 1.Satou T (2000) Head and neck tumor. In: Nomura AKK, Honjyou I, Inuyama A (eds) Clinical textbook of the ear, nose and throat regions 21, edn, vol 17. Nakayama-syoten, Tokyo, pp 17–28Google Scholar
- 2.Ridge JA, Glisson BS, Lango MN et al (2008) Head and neck tumors. In Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (eds) Cancer management: a multidisciplinary approach, 11 edn. CMPMedica, Lawrence Google Scholar
- 5.Terhaard CH, Lubsen H, Rasch CR, Levendag PC, Kaanders HH, Tjho-Heslinga RE, van Den Ende PL, Burlage F, Dutch Head and Neck Oncology Cooperative Group (2005) The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 61:103–111PubMedCrossRefGoogle Scholar
- 9.Kankaanranta L, Seppälä T, Koivunoro H, Saarilahti K, Atula T, Collan J, Salli E, Kortesniemi M, Uusi-Simola J, Mäkitie A, Seppänen M, Minn H, Kotiluoto P, Auterinen I, Savolainen S, Kouri M, Joensuu H (2007) Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. Int J Radiat Oncol Biol Phys 69:475–482PubMedCrossRefGoogle Scholar
- 11.Ono K, Masunaga S, Kinashi Y et al (2006) Neutron irradiation under continuous BPA injection for solving the problem of heterogenous distribution of BPA. In: Advances in neutron capture therapy. Takamatsu, pp 27–30Google Scholar
- 14.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
- 19.Unger KR, Lominska CE, Deeken JF, Davidson BJ, Newkirk KA, Gagnon GJ, Hwang J, Slack RS, Noone AM, Harter KW (2010) Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys (Epub ahead of print)Google Scholar